Schering-Plough licenses ALK-Abello's immunotherapeutics; rights returned
Executive Summary
Schering-Plough has licensed exclusive US, Canadian, and Mexican development, marketing, and distribution rights to three of ALK-Abello's (immunotherapeutics) allergy immunotherapeutics for grass pollen, house dust mites, and ragweed.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice